Filtered By:
Condition: Ischemic Stroke
Therapy: Dialysis

This page shows you your search results in order of relevance. This is page number 13.

Order by Relevance | Date

Total 281 results found since Jan 2013.

Erythropoiesis-stimulating agents and thrombotic events in dialysis patients
Erythropoiesis-stimulating agents (ESA) have been associated with a higher cardiovascular event and mortality rate in dialysis patients. The ESA-associated risk of arterial thrombotic events is mainly based on composite endpoints of anemia-correction trials targeting high hemoglobin levels. The ESA-associated risk of venous thromboembolism (VTE) has not been studied in dialysis patients yet. We therefore aimed to determine the association between ESA use and dose with ischemic stroke, myocardial infarction (MI) and VTE.
Source: Thrombosis Research - August 1, 2014 Category: Hematology Authors: Marit M. Suttorp, Tiny Hoekstra, Gürbey Ocak, Anouk T.N. van Diepen, Ilka Ott, Moshe Mittelman, Ton J. Rabelink, Raymond T. Krediet, Friedo W. Dekker Source Type: research

Age may explain the association of an early dialysis initiation with poor survival
Conclusion: History of ischemic heart disease, serum albumin and dialysis start before 2005 were risk factors for mortality in ESRD patients. Older age is usually associated with early dialysis initiation, so age adjustment is needed to perform studies aimed to calculate the effect of eGFR at dialysis initiation on survival.
Source: QJM - October 24, 2014 Category: Internal Medicine Authors: Soler, M. J., Montero, N., Pascual, M. J., Barrios, C., Marquez, E., Orfila, M. A., Cao, H., Arcos, E., Collado, S., Comas, J., Pascual, J. Tags: Original papers Source Type: research

Clopidogrel Use in End‐Stage Kidney Disease
In conclusion, current evidence suggests that ESKD patients may not derive the same benefits from clopidogrel therapy as the general population and this therapy may be associated with harm. Properly designed observational studies and randomized controlled trials are needed to establish the role of clopidogrel in patients with ESKD, the use of platelet assays to tailor therapy, and the role of other antiplatelet agents such as prasugrel or ticagrelor in patients who exhibit high on‐treatment residual platelet reactivity.
Source: Seminars In Dialysis - November 1, 2014 Category: Hematology Authors: Bassem Y. Tanios, Houssam S. Itani, Deborah L. Zimmerman Tags: Review Source Type: research

Clopidogrel Use in End-Stage Kidney Disease.
In conclusion, current evidence suggests that ESKD patients may not derive the same benefits from clopidogrel therapy as the general population and this therapy may be associated with harm. Properly designed observational studies and randomized controlled trials are needed to establish the role of clopidogrel in patients with ESKD, the use of platelet assays to tailor therapy, and the role of other antiplatelet agents such as prasugrel or ticagrelor in patients who exhibit high on-treatment residual platelet reactivity. PMID: 25476742 [PubMed - as supplied by publisher]
Source: Seminars in Dialysis - December 5, 2014 Category: Urology & Nephrology Authors: Tanios BY, Itani HS, Zimmerman DL Tags: Semin Dial Source Type: research

Preoperative renal function and surgical outcomes in patients with acute type A aortic dissection
CONCLUSIONS Preoperative estimated glomerular filtration rate can effectively predict the need for renal replacement therapy after surgery for acute type A aortic dissection. However, it is not an effective diagnostic tool to predict in-hospital mortality. The complexity of the characteristics of patients who undergo surgical procedures may make prediction of surgical outcomes difficult. Risk models to predict hospital mortality and morbidities are needed to assist clinicians in determining the optimal treatment.
Source: Interactive CardioVascular and Thoracic Surgery - March 19, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Imasaka, K.-i., Tayama, E., Tomita, Y. Tags: Great vessels, Aorto-iliac disease, Thoracic aorta Vascular Source Type: research

Subarachnoid Hemorrhage as the Initial Neurologic Manifestation in Thrombotic Thrombocytopenic Purpura (P6.014)
Conclusion: Upon review of the literature, ischemic infarction and intracerebral hemorrhage are uncommon complications of TTP. Our case demonstrates a unique case of subarachnoid hemorrhage as the initial neurological manifestation of TTP.Disclosure: Dr. Wei has nothing to disclose. Dr. Ramesh has nothing to disclose. Dr. Farmakidis has nothing to disclose. Dr. Nalleballe has nothing to disclose. Dr. JADEJA has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Wei, J., Ramesh, A., Farmakidis, C., Nalleballe, K., Jadeja, N. Tags: Cerebrovascular Disease and Interventional Neurology II ePosters Source Type: research

Effects of Withdrawing Versus Continuing Renin-Angiotensin Blockers on Incidence of Acute Kidney Injury in Patients with Renal Insufficiency Undergoing Cardiac Catheterization: Results from the CAPTAIN Trial
Conclusion In patients with moderate renal insufficiency undergoing cardiac catheterization, withholding ACEI/ARB reduced (without statistical significance) the incidence of contrast-induced AKI. Additionally, a lower rise in post procedural creatinine levels was also noted. This low cost intervention could be considered when referring a patient for cardiac catheterization.
Source: American Heart Journal - April 22, 2015 Category: Cardiology Source Type: research

Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial
Conclusion In this pilot study of patients with moderate renal insufficiency undergoing cardiac catheterization, with-holding ACEI/ARB resulted in a non-significant reduction in contrast-induced AKI and a significant reduction in post-procedural rise of creatinine. This low cost intervention could be considered when referring a patient for cardiac catheterization.
Source: American Heart Journal - May 12, 2015 Category: Cardiology Source Type: research

SuO001 * RISK OF ISCHAEMIC STROKE FOR INCIDENT PATIENTS TREATED WITH PERITONEAL DIALYSIS VERSUS HAEMODIALYSIS
Source: Nephrology Dialysis Transplantation - May 21, 2015 Category: Urology & Nephrology Authors: Stack, A. G., Elsayed, M. E., Sharif, M. U., Clarke Moloney, M., Ferguson, J. P. Tags: DIALYSIS CARDIOVASCULAR PATHOPHYSIOLOGY Source Type: research

Sp372 * increased risk of ischemic stroke in patients with chronic kidney disease after recurrent dysnatremia: a nationwide population based cohort study in taiwan
Source: Nephrology Dialysis Transplantation - May 21, 2015 Category: Urology & Nephrology Authors: Chung, M.-C., Yu, T.-M., Wu, M.-J., Chang, C.-H., Muo, C.-H., Shu, K.-H., Chen, H.-W., Chung, C.-J. Tags: CHRONIC KIDNEY DISEASE. CLINICAL EPIDEMIOLOGY - 2 Source Type: research

Outcomes of Open Repair of Mycotic Descending Thoracic and Thoracoabdominal Aortic Aneurysms
Conclusions Open repair of mycotic descending thoracic and thoracoabdominal aortic aneurysms remains the gold standard of therapy. Aggressive intraoperative debridement with in situ prosthetic reconstruction permits a high rate of success in this very high risk cohort of patients. Lifelong antibiotic suppression therapy may prevent late prosthetic graft infection.
Source: The Annals of Thoracic Surgery - August 14, 2015 Category: Cardiovascular & Thoracic Surgery Source Type: research

Outcomes of Open Repair of Mycotic Descending Thoracic and Thoracoabdominal Aortic Aneurysms.
CONCLUSIONS: Open repair of mycotic descending thoracic and thoracoabdominal aortic aneurysms remains the gold standard of therapy. Aggressive intraoperative debridement with in situ prosthetic reconstruction permits a high rate of success in this very high risk cohort of patients. Lifelong antibiotic suppression therapy may prevent late prosthetic graft infection. PMID: 26277557 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - August 13, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Lau C, Gaudino M, de Biasi AR, Munjal M, Girardi LN Tags: Ann Thorac Surg Source Type: research

Dabigatran treatment simulation in patients undergoing maintenance haemodialysis.
This study simulated the dose-exposure relationship of dabigatran in patients undergoing haemodialysis. Dabigatran exposure was modelled at once- and twice-daily doses of 75 mg, 110 mg and 150 mg and at variations in non-renal clearance and dialysis settings. Resultant dose exposure (area under the curve [AUC]) was compared with values simulated from typical patients in the RE-LY® trial (based on a previously characterised pharmacometric model). In this simulation, all twice-daily dosages resulted in exposures above those simulated from typical RE-LY patients (1.5- to 3.3-fold increase in AUC) and thus may not be optimal ...
Source: Thrombosis and Haemostasis - October 15, 2015 Category: Hematology Authors: Liesenfeld KH, Clemens A, Kreuzer J, Brueckmann M, Schulze F Tags: Thromb Haemost Source Type: research

Clinical Outcomes of Drug-Eluting Stents vs. Bare-Metal Stents in Acute Myocardial Infarction Patients Under Dialysis　- A Nationwide Cohort Study.
CONCLUSIONS: Among AMI patients on dialysis undergoing percutaneous coronary interventions, DES implantation significantly reduced the risk of recurrent MI, CV death and all-cause mortality compared with BMS implantation. PMID: 26581755 [PubMed - as supplied by publisher]
Source: Circulation Journal - November 19, 2015 Category: Cardiology Authors: Chen DY, Mao CT, Tsai ML, Hsieh MJ, Lin YS, Cherng WJ, Wen MS, Wang CH, Hsieh IC, Hung MJ, Chen CC, Chen TH Tags: Circ J Source Type: research